FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Leukocyte topics
Leukocytes
Immunogenic
Stem Cells
Immune System
Animal Model
Human Leukocyte Antigen
Transgenic
Stimulator
Macrophage
Thromboxane
Attenuated
Fibronectin
Chronic Obstructive Pulmonary Disease
Antagonist
Vaccination

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Leukocyte patents



      
           
This page is updated frequently with new Leukocyte-related patent applications. Subscribe to the Leukocyte RSS feed to automatically get the update: related Leukocyte RSS feeds. RSS updates for this page: Leukocyte RSS RSS


Date/App# patent app List of recent Leukocyte-related patents
08/14/14
20140227711
 Genotoxicity as a biomarker for inflammation patent thumbnailGenotoxicity as a biomarker for inflammation
The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of dna damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation.
08/14/14
20140227272
 Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains patent thumbnailAnti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains
The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian t-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells are also contemplated..
08/07/14
20140220572
 Method and system to detect, diagnose, and monitor the progression of alzheimer's disease patent thumbnailMethod and system to detect, diagnose, and monitor the progression of alzheimer's disease
Various embodiments provide methods for the detection, the diagnosis, and/or the progression monitoring of alzheimer's disease by observing the epigenetic markers in leukocytes. Methods for determining a state of alzheimer's disease are provided.
07/31/14
20140212960
 Leukocyte measurement device and reagent kit patent thumbnailLeukocyte measurement device and reagent kit
A leukocyte measurement device is provided with a spread inspection window at a position separated from an opening part along a spreading direction of a blood-derived sample in a carrier, for making the carrier visible from outside. When the blood-derived sample is dropped from the opening part, leukocytes contained in the blood-derived sample are captured by the carrier in the vicinity of a dropping position, while erythrocytes and/or hemoglobin and the like spread through the carrier from the dropping position into a predetermined direction.
07/10/14
20140190888
 Methods, systems and devices for separating tumor cells patent thumbnailMethods, systems and devices for separating tumor cells
Embodiments of the present disclosure are directed to the separation/capture of specific cells and/or contaminants, as well as the determination, monitoring, and treatment of cancer. Moreover, some embodiments are directed to methods, systems and devices for removing cancer, stem and/or tumor cells in vivo or in vitro from a bodily fluid to prevent or impede the proliferation of a cancer.
07/03/14
20140186345
 Method of administering an antibody patent thumbnailMethod of administering an antibody
Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month..
06/26/14
20140179807
 Module-level analysis of peripheral blood leukocyte transcriptional profiles patent thumbnailModule-level analysis of peripheral blood leukocyte transcriptional profiles
The present invention includes an apparatus, system and method for the development and use of transcriptional modules by obtaining individual gene expression levels from cells obtained from one or more patients with a disease or condition; recording the expression value for each gene in a table that is divided into clusters; iteratively selecting gene expression values for one or more transcriptional modules by: selecting for the module the genes from each cluster that match in every disease or condition; removing the selected genes from the analysis; and repeating the process of gene expression value selection for genes that cluster in a sub-fraction of the diseases or conditions; and iteratively repeating the generation of modules.. .
06/26/14
20140179659
 Method for suppressing surgical site infection and column to be used for the method patent thumbnailMethod for suppressing surgical site infection and column to be used for the method
An object of the present invention is to provide a method for suppressing surgical site infections (ssi) that have occurred at extremely high incidence rates at the time of surgical operations and particularly surgical operations on digestive system organs, and to provide a column to be used for the method. According to the present invention, a method is provided for suppressing surgical site infections, which comprises the steps of: (a) administering a chemotherapeutic drug for treating and/or preventing a surgical site infection; and (b) collecting blood from a surgical subject and removing leukocytes that comprise neutrophils from the blood during or within 24 hours after surgical operation, and then returning the blood from which the leukocytes have been removed to the surgical subject.
06/19/14
20140170169
 Blocking antibody for transplantation patent thumbnailBlocking antibody for transplantation
A method can include administering a donor-specific human leukocyte antigen antibody to a tissue transplant recipient where the antibody is an immunoglobulin g subclass 4 antibody (g4). Various other examples of devices, assemblies, systems, methods, etc., are also disclosed..
06/05/14
20140154772
 Inhibitors of human phosphatidylinositol 3-kinase delta patent thumbnailInhibitors of human phosphatidylinositol 3-kinase delta
Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (pi3kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which pi3kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit pi3kδ, while not significantly inhibiting activity of other pi3k isoforms.
05/29/14
20140147470
Methods of predicting host responsiveness to cancer immunotherapies by ex vivo induction of leukocyte-function-associated mrnas
Embodiments of the invention relate generally to ex vivo methods of quantifying expression of leukocyte-function associated mrnas and using the quantification to characterize an individual's potential responsiveness to cancer immunotherapy. Certain embodiments relate to methods to monitor the efficacy of ongoing cancer immunotherapy by evaluating expression of leukocyte-function associated mrnas genes before and administration of an anti-cancer immunotherapy regimen..
05/22/14
20140141045
Allogeneic tumor cell vaccination
The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions.
05/22/14
20140140984
Composition comprising herbal extracts or fermented products thereof having lactic acid bacteria for preventing or treating respiratory diseases
The present invention relates to a composition for preventing or treating respiratory diseases, and more particularly, to a pharmaceutical composition, and to a health food, comprising extracts of herbal mixtures or fermented products thereof having lactic acid bacteria as effective ingredients for preventing or treating respiratory diseases, wherein the herbal mixtures comprise: sophora flavascens, radix glycyrrhizae, flos lonicerae, angelicae gigantis radix, aralia continentalis, inula helenium, saposhnikoviae radix, zizyphus spinosa, houttuynia cordata, forsythiae fructus, arctium lappa, herba epimedii, ginseng, lithospermi radix, sanguisorbae radix, cnidii rhizoma, scrophulariae radix, and polygoni cuspidati radix. The herbal extracts or fermented products thereof having lactic acid bacteria exhibit the effects of significantly lowering an airway resistance value; reducing the numbers of leukocytes, neutrophilic leukocytes, lymphocytes, eosinocytes, and basophil leukocytes to levels similar to that of a normal group; and reducing the infiltration of inflammatory cells and eosinocyte cells near ahr on lung tissues.
05/15/14
20140134137
Use of stem cells to reduce leukocyte extravasation
The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes.
05/01/14
20140121224
Quinazolinones as inhibitors of human phosphatidyositol 3-kinase delta
Compounds that inhibit pi3kδ activity, including compounds that selectively inhibit pi3kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (pi3kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which pi3kδ plays a role in leukocyte function, using the compounds also are disclosed..
05/01/14
20140121223
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Compounds that inhibit pi3kδ activity, including compounds that selectively inhibit pi3kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (pi3kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which pi3kδ plays a role in leukocyte function, using the compounds also are disclosed..
05/01/14
20140120530
Method for classifying/counting leukocytes, reagent kit for classifying leukocytes, and reagent for classifying leukocytes
The present invention provides a method for classifying and counting leukocytes which allows classification and count of normal leukocytes as well as discrimination between blast cells and atypical lymphocytes. The present invention also provides a regent kit and reagent for classifying leukocyte which are used for classifying and counting leukocytes in biological samples..
04/10/14
20140100188
Phenotyping tumor-infiltrating leukocytes
The present disclosure relates to an immune signature of tumor infiltrating leukocytes. In particular, the disclosure provides methods and kits for determining the immune signature of tumor infiltrating leukocytes for use in assessing risk of cancer recurrence and long term survival, and for developing a treatment regimen for a cancer patient..
04/10/14
20140099632
Preparation and use of nucleated red blood cell simulating particles and hematology control mixtures
The present disclosure provides a nucleated red blood cell simulating particle, which may be leukocytes bound to a fluorescent-staining inhibitor capable of stably binding to the nucleus or a nucleic acid in a cell so as to reduce the binding capacity of the particles to a fluorescent dye during their detection. The present disclosure also provides a method for preparing nucleated red blood cell simulating particles, including the following steps: (a) obtaining purified leukocytes; (b) suspending the leukocytes in a cell treatment solution containing a fluorescent-staining inhibitor which stably binds to the nucleus or a nucleic acid in a cell, and (c) washing the obtained product.
04/10/14
20140099254
Combination therapy for inducing immune response to disease
The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies.
03/20/14
20140080151
Anti-himf antibodies to treat lung diseases
Hypoxia induced mitogenic factor (himf) is a member of the “found in inflammatory zone” (fizz)/resistin family of proteins and has potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. The receptor/binding partners for this family of proteins have been largely unknown.
03/20/14
20140080132
Method and kit for predicting cytotoxicity
A method for predicting adcc activity in a subject, the method comprising the steps of: (a) preparing a biological sample from the subject, said sample including a leukocyte, (b) bringing a portion of the biological sample and an antibody into contact with each other, (c) detecting expression of at least one marker of adcc activity selected from the group consisting of tumor necrosis factor super family 15, chemokine cxcl3, and interleukin 6 in the leukocyte in (i) the portion of the sample brought into contact with the antibody and in (ii) another portion of the sample not brought into contact with the antibody, (d) comparing an expression level in portion (i) with the expression level in portion (ii); and (e) predicting presence of the cytotoxic activity when the expression level in portion (i) is higher than the expression level in portion (ii). .
03/13/14
20140073586
Compositions for the treatment of cancer, and methods for testing and using the same
A composition comprising leukotoxin proteins isolated from a bacterium is provided. In this composition, greater than 85% of the leukotoxin proteins are chemically modified at a basic amino acid residue, and the proteins induce cell death in myeloid leukocytes, while remaining substantially non-toxic to lymphoid leukocytes, lymphocytes, and red blood cells.
03/13/14
20140073569
Method for generating immunomodulatory cells, the cells prepared therefrom and use thereof
The present invention develops a straightforward and rapid method for generating immunomodulatory cells from peripheral mononuclear cells, comprising treating peripheral mononuclear cells with a hepatocyte growth factor (hgf) to induce differentiation of the peripheral mononuclear cells into immunomodulatory leukocytes. The present invention also provides an immunomodulatory cell prepared according to this method.
02/27/14
20140056929
Immunomodulation by controlling interferon-gamma levels with the long non-coding rna nest
Compositions and methods of modulating an immune response by controlling levels of interferon-gamma (ifn-γ) production by leukocytes are disclosed. Adjustment of ifn-γ levels is achieved by increasing or decreasing the activity of nest (nettoie salmonella pas theiler's [cleanup salmonella not theiler's]), a long non-coding rna that induces expression of ifn-γ.
02/20/14
20140051117
Mass spectrometric diagnosis of septicemia
The invention mainly relates to the mass spectrometric identification of pathogens in blood cultures from bloodstream infections (septicemia). The invention provides a method with which microbial pathogens can be separated in purified form from blood after a relatively brief cultivation in a blood culture flask, without any interfering human proteins or any residual fractions of blood particles such as erythrocytes and leukocytes, and can be directly identified by mass spectrometric measurement of their protein profiles.
02/20/14
20140050700
Ex-vivo treatment of peripheral blood leukocytes with ifn-lambda
The present invention provides a method of treating th2-associated diseases and disorders by modulating the expression or secretion of il-4, il-5 and il-13 using interferon lambda (ifn-λ). For th2-associated diseases and disorders, cells of a patient having a th2-associated disease or disorder are treated ex vivo, with ifn-λ and returned to the patient.
02/13/14
20140042081
Filter for removing substances from blood or from blood derivatives, and a method for obtaining it
A filter for removing substances, including leukocytes and platelets by way of non-limiting example, from whole blood or from blood derivatives, the filter includes a casing containing a layered filter element, at least one layer of this latter being coated with polyurethane; this polyurethane has a number average molecular weight between 10,000 and 20,000 dalton. A method for forming the layered filter element for a filter such as mentioned above, in which at least one layer of this filter element is impregnated with polyurethane by immersing it in a container of a mixture in which the polyurethane is present.
02/06/14
20140038230
A simple and affordable method for immunophenotyping using a microfluidic chip sample preparation with image cytometry
The enumeration of cells in fluids by flow cytometry is widely used across many disciplines such as assessment of leukocyte subsets in different bodily fluids or of bacterial contamination in environmental samples, food products and bodily fluids. For many applications the cost, size and complexity of the instruments prevents wider use, for example, cd4 analysis in hiv monitoring in resource-poor countries.
02/06/14
20140038179
Reagent and reagent kit for analysis of immature leukocyte
At least one dye for staining nucleic acid selected from the dyes of the formulae (i) and (ii), wherein x− is an anion.. .
02/06/14
20140037596
Use of stem cells to reduce leukocyte extravasation
The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in vascular endothelial cells.
01/23/14
20140023670
Cancer vaccine composition
A cancer vaccine composition for human leukocyte antigen (hla)-a*0206-positive persons, comprising a protein product of the tumor suppressor gene wt1 or a partial peptide thereof.. .
01/16/14
20140017719
Reagent for blood cell counting and blood analysis method
Disclosed is a novel reagent for blood cell counting and a novel blood analysis method, which enable blood cells such as leukocytes to be counted with high accuracy by dissociating platelet aggregates in capillary blood collected from a living body. The reagent for blood cell counting is used to dilute capillary blood collected from a living body to prepare a blood sample in order to count blood cells in the collected capillary blood using a particle analyzer, and is an aqueous solution containing a chloroquine salt..
01/16/14
20140017218
Method for inducing immune tolerance using viable polymer-modified allogeneic leukocytes
This invention relates to cellular-based therapies for increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition.
01/16/14
20140017203
Recombinant adenovirus expressing alpha-a-crystallin gene and gene therapy for retinalvascular disease using the same
The present invention relates to a recombinant adenovirus expressing an αa-crystallin gene, and gene therapy for retinal vascular disease using the recombinant adenovirus. Gene therapy using the recombinant adenovirus comprising an αa-crystallin gene of the present invention increases the expression level of the αa-crystallin gene in the damaged retinal pericytes to suppress pericyte loss and death, retinal vascular leakage, and leukocyte adhesion surrounding retinal vessels, thereby protecting the pericytes.
01/09/14
20140012104
Method for observing, identifying, and detecting blood cells
The invention provides a method for the observation, identification, and detection of blood cells, which comprises a label-free third harmonic generation (thg) tomography having a property of least injury. Submicron morphologies and granularities of blood cells can be revealed and reflected through this method.
01/09/14
20140011205
Leukocyte activation and methods of use thereof
Described herein are compositions, methods and/or kits for determining the likelihood of a pregnant subject delivering at term, or developing a disorder associated with pregnancy. These compositions, methods and/or kits feature the measurement of the chemotactic activity of peripheral leukocytes, the measurement of ccl2 mrna expression or the measurement of fp or otr protein expression..
01/09/14
20140010825
Diagnostic and therapeutic potential of hla-e monospecific monoclonal igg antibodies directed against tumor cell surface and soluble hla-e
Provided herein are compositions comprising purified antibodies and fragments thereof that are specifically immunoreactive to only human leukocyte antigen e (hla-e) but not to other hla ia and hla-ib alleles. Also provided are methods of their making and diagnostic and therapeutic applications.
01/09/14
20140008288
Method for the elimination of leukocytes from blood
The invention relates to a method for reducing the number of leukocytes in blood through treating the blood in an arrangement of a plurality of fibers based on organic polymers, whereby the blood is channeled along the fibers and whereby the reduction in leukocytes from the blood occurs essentially through adsorption on the fibers, characterized in that the plurality of fibers based on organic polymers is fixed in a housing with an inlet arrangement and an outlet arrangement, and that the blood is channeled via the inlet arrangement into the housing, flows through the housing with the plurality of fibers made from organic polymers, and exits the housing via the outlet arrangement, that the arrangement of the fibers shows a high degree of order, that the blood flows along the external surface of the fibers, and that the fibers cause a generation of the complement activation product c5a in a concentration of at least 10 μg per m2 of fiber surface.. .
01/02/14
20140004091
Activated leukocyte composition and uses for wound healing
Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.. .
01/02/14
20140004049
Nanoprobes for sensing of reactive oxygen and reactive nitrogen species
For whole animal in-situ and real-time imaging of inflammation, a dual-color fluorescent nanoprobe is provided for the detection of reactive oxygen and nitrogen species (rons) in inflammatory microenvironments. The nanoprobes of the disclosure are a rons-responsive energy transferring nanosystem of a fluorescent conjugated polymer core and a peg-shell linked with rons-sensing antennae as a fret acceptor.
12/26/13
20130344480
Method for treating a blood component containing sample
Provided is a treatment method for damaging an erythrocyte and a leukocyte while suppressing damage to cells other than blood cells present in blood. In an embodiment, the disclosure relates to a method for treating a sample containing blood components, the method including mixing a sample containing blood components with a surfactant a, where the surfactant a is a nonionic surfactant represented by general formula r1—o-(eo)n-r2 (i)..
12/19/13
20130338164
Multimeric vla-4 antagonists comprising polymers moieties
Disclosed are conjugates which bind vla-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by vla-4.
12/19/13
20130338089
Methods and compounds for modulating the secretion or expression of adhesion proteins or angiopoietins of cells
This invention provides methods, processes, compounds and compositions for modulating the gene expression or secretion of adhesion proteins, angiopoietins or their receptors to cure diseases, for anti-angiogenesis and for treating parasites, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, myosin, vitronectin, collagen, laminin, glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, cd 54, cam, elastin and fak; wherein the angiopoietins comprise angiopoietin 1, angiopoietin 2, angiopoietin 3, angiopoietin 4, angiopoietin 5, angiopoietin 6, angiopoietin 7, angiopoietin-like 1, angiopoietin-like 2, angiopoietin-like 3, angiopoietin-like 4, angiopoietin-like 5, angiopoietin-like 6, and angiopoietin-like 7; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, cns cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphatic cancer, pancreas cancer, stomach cancer and thyroid cancer.. .


Popular terms: [SEARCH]

Leukocyte topics: Leukocytes, Immunogenic, Stem Cells, Immune System, Animal Model, Human Leukocyte Antigen, Transgenic, Stimulator, Macrophage, Thromboxane, Attenuated, Fibronectin, Chronic Obstructive Pulmonary Disease, Antagonist, Vaccination

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Leukocyte for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukocyte with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2825

3271

2 - 1 - 71